These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27780195)

  • 1. Comment on 'Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome'.
    Dell'Oglio P; Stabile A; Gandaglia G; Briganti A
    Br J Cancer; 2017 Jan; 116(3):e3. PubMed ID: 27780195
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to 'Comment on "Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome"'.
    Berney DM
    Br J Cancer; 2017 Jan; 116(3):e4. PubMed ID: 27780194
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Prognostic Significance of Percentage and Architectural Types of Contemporary Gleason Pattern 4 Prostate Cancer in Radical Prostatectomy.
    Villers A; Rubin MA
    Eur Urol; 2017 Feb; 71(2):301. PubMed ID: 27687819
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: Clinical significance of prospectively assigned gleason tertiary pattern 4 in contemporary Gleason score 3 + 3 = 6 prostate cancer.
    Kryvenko ON; Epstein JI
    Prostate; 2016 Sep; 76(12):1130-1. PubMed ID: 27225506
    [No Abstract]   [Full Text] [Related]  

  • 5. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score.
    Epstein JI; Zelefsky MJ; Sjoberg DD; Nelson JB; Egevad L; Magi-Galluzzi C; Vickers AJ; Parwani AV; Reuter VE; Fine SW; Eastham JA; Wiklund P; Han M; Reddy CA; Ciezki JP; Nyberg T; Klein EA
    Eur Urol; 2016 Mar; 69(3):428-35. PubMed ID: 26166626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens.
    Sauter G; Steurer S; Clauditz TS; Krech T; Wittmer C; Lutz F; Lennartz M; Janssen T; Hakimi N; Simon R; von Petersdorff-Campen M; Jacobsen F; von Loga K; Wilczak W; Minner S; Tsourlakis MC; Chirico V; Haese A; Heinzer H; Beyer B; Graefen M; Michl U; Salomon G; Steuber T; Budäus LH; Hekeler E; Malsy-Mink J; Kutzera S; Fraune C; Göbel C; Huland H; Schlomm T
    Eur Urol; 2016 Apr; 69(4):592-598. PubMed ID: 26542947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
    Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
    Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A nationwide trend away from radical prostatectomy for Gleason Grade Group 1 prostate cancer.
    John JB; Pascoe J; Fowler S; Walton T; Johnson M; Challacombe B; Dickinson AJ; Aning J; McGrath JS
    BJU Int; 2022 Mar; 129(3):311-314. PubMed ID: 34825460
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. External validation of the UCSF-CAPRA (University of California, San Francisco, Cancer of the Prostate Risk Assessment) in Japanese patients receiving radical prostatectomy.
    Ishizaki F; Hoque MA; Nishiyama T; Kawasaki T; Kasahara T; Hara N; Takizawa I; Saito T; Kitamura Y; Akazawa K; Takahashi K
    Jpn J Clin Oncol; 2011 Nov; 41(11):1259-64. PubMed ID: 21940731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New prostate cancer grade grouping system predicts survival after radical prostatectomy.
    Erickson A; Sandeman K; Lahdensuo K; Nordling S; Kallajoki M; Seikkula H; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
    Hum Pathol; 2018 May; 75():159-166. PubMed ID: 29447924
    [No Abstract]   [Full Text] [Related]  

  • 13. [Prostatectomy vs. "watchful waiting" in early prostate cancer].
    Markun S
    Praxis (Bern 1994); 2014 Jul; 103(15):909-10. PubMed ID: 25051936
    [No Abstract]   [Full Text] [Related]  

  • 14. An end to the phenomenon of 'upgrading' in early prostate cancer?
    Emberton M
    BJU Int; 2017 Apr; 119(4):506-507. PubMed ID: 28319353
    [No Abstract]   [Full Text] [Related]  

  • 15. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
    Liesenfeld L; Kron M; Gschwend JE; Herkommer K
    J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concordance of biopsy and pathologic ISUP grading in salvage radical prostatectomy patients for recurrent prostate cancer.
    Preisser F; Würnschimmel C; Pose RM; Heinze A; Steuber T; Michl U; Salomon G; Mandel P; Graefen M; Tilki D
    Prostate; 2022 Feb; 82(2):254-259. PubMed ID: 34807461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncologic outcomes at 10 years following robotic radical prostatectomy.
    Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
    Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term cancer control after radical prostatectomy and bilateral pelvic lymph node dissection for pT3bN0M0 prostate cancer in the prostate-specific antigen era.
    Fairey AS; Daneshmand S; Skinner EC; Schuckman A; Cai J; Lieskovsky G
    Urol Oncol; 2014 Feb; 32(2):85-91. PubMed ID: 24183191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does Subclassification of Pathologically Organ Confined (pT2) Prostate Cancer Provide Prognostic Discrimination of Outcomes after Radical Prostatectomy?
    Nguyen DP; Vertosick EA; Sharma V; Corradi RB; Vilaseca A; Takeda T; Sjoberg DD; Benfante N; Fine SW; Reuter VE; Scardino PT; Eastham JA; Karnes RJ; Touijer KA
    J Urol; 2018 Jun; 199(6):1502-1509. PubMed ID: 29307681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Age With Risk of Adverse Pathological Findings at Radical Prostatectomy in Men With Gleason Score 6 Prostate Cancer.
    Kim DW; Chen MH; Huland H; Graefen M; Tilki D; D'Amico AV
    JAMA Netw Open; 2020 Apr; 3(4):e202041. PubMed ID: 32239219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.